Ligand Pharmac-B

Forecast & Rating11 analysts currently cover Ligand Pharmac-B, with about 90.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $342.82, about 19.8% upside from the current price of $286.17. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 49.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Ligand Pharmac-B closely still see room for the stock to rise. Data as of Aug 17, 2026; for reference only and not investment advice.